CLINICAL_TRIALS trial_result · 2012-08-10

Clinical Trial Update: Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia [Phase 2]

Summary

Phase 2 trial update reporting results for subcutaneous alemtuzumab (CAMPATH, MabCampath) in relapsed/refractory B-cell chronic lymphocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: B-Cell Chronic Lymphocytic Leukemia (B-CLL) | Phase 2 | Status: COMPLETED | Results posted: 2012-08-10